登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
CAR-T Following ASCT for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (R/R B-NHL) With High-Risk Prognostic Factors
ClinicalTrials.gov 上登记的一项淋巴瘤开放试验,由上海交通大学医学院附属瑞金医院牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT06365671,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 7
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(7 项)收起清单
18 岁 至 未注明;性别:不限
登记记录的入选字段
Histologically confirmed B-cell non-Hodgkin's lymphoma including the following types
入选标准第 1 条
Partial response (PR) as best response after at least 6 cycles of first-line therapy (biopsy-proven residual disease is needed for individuals with Deauville score of 4)
入选标准第 10 条
Relapsed or refractory diseases fulfilling one of the following criteria (individuals must have received anti-CD20 monoclonal antibody and anthracycline-containing chemotherapy regimen)
入选标准第 7 条
Primary refractory disease, defined as disease progression after first-line immunochemotherapy or disease progression within 6 weeks of the end of the last chemotherapy
入选标准第 8 条
Stable disease (SD) as best response after at least 4 cycles of first-line therapy
入选标准第 9 条
PR as best response after at least 2 cycles of second-line therapy
入选标准第 11 条
Disease relapse ≤12 months after the completion of first-line immunochemotherapy
入选标准第 12 条
Relapsed or refractory disease after ≥2 lines of chemotherapy
入选标准第 13 条
Prior chimeric antigen receptor cellular immunotherapy targeting CD19
排除标准第 5 条
Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
入选标准第 15 条
Serum alanine aminotransferase (ALT/AST) ≤ 3 upper limit of normal (ULN)
入选标准第 18 条
Total bilirubin ≤1.5 mg/dL(<3 times ULN in patients with Gilbert's syndrome, cholestasis due to hepatoportal compression adenopathy, biliary obstruction in patients with liver involvement or lymphoma)
入选标准第 19 条
Serum creatinine ≤1.5 ULN, or creatinine clearance (as estimated by Cockcroft Gault) ≥ 30 mL/min
入选标准第 20 条
Active HBV or HCV infection, defined as HBV-DNA or HCV-DNA levels above the normal upper limit, with or without abnormal liver function. Individuals with positive HBsAg or HBcAb should receive antiviral prophylaxis for at least 12 months after CAR-T cells infusion.
排除标准第 2 条
History of HIV infection
排除标准第 4 条
Pregnant or lactating patients
排除标准第 6 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);影像与可测量病灶。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06365671,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Histologically confirmed B-cell non-Hodgkin's lymphoma including the following types diffuse large B-cell lymphoma high-grade B-cell lymphoma with or without MYC and BLC2 and/or BCL6 rearrangement transformed lymphoma primary mediastinal large B-cell lymphoma follicular lymphoma (FL) Relapsed or refractory diseases fulfilling one of the following criteria (individuals must have received anti-CD20 monoclonal antibody and anthracycline-containing chemotherapy regimen) Primary refractory disease, defined as disease progression after first-line immunochemotherapy or disease progression within 6 weeks of the end of the last chemotherapy Stable disease (SD) as best response after at least 4 cycles of first-line therapy Partial response (PR) as best response after at least 6 cycles of first-line therapy (biopsy-proven residual disease is needed for individuals with Deauville score of 4) PR as best response after at least 2 cycles of second-line therapy Disease relapse ≤12 months after the completion of first-line immunochemotherapy Relapsed or refractory disease after ≥2 lines of chemotherapy Presence of at least one of the following high-risk prognostic factors: (1) extranodal involvement; (2) maximum diameter of the bulky mass ≥5 cm; (3) TP53 gene alterations Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 Eligible for HDCT/ASCT based on the investigator's assessment and are scheduled to undergo an ASCT sequential CAR-T treatment regimen Adequate renal and hepatic function defined as: Serum alanine aminotransferase (ALT/AST) ≤ 3 upper limit of normal (ULN) Total bilirubin ≤1.5 mg/dL(<3 times ULN in patients with Gilbert's syndrome, cholestasis due to hepatoportal compression adenopathy, biliary obstruction in patients with liver involvement or lymphoma) Serum creatinine ≤1.5 ULN, or creatinine clearance (as estimated by Cockcroft Gault) ≥ 30 mL/min Cardiac ejection fraction ≥ 40% Baseline oxygen saturation > 95% on room air Life expectancy ≥3 months排除标准:Exclusion Criteria:
History of autologous or allogeneic stem cell transplantation Active HBV or HCV infection, defined as HBV-DNA or HCV-DNA levels above the normal upper limit, with or without abnormal liver function. Individuals with positive HBsAg or HBcAb should receive antiviral prophylaxis for at least 12 months after CAR-T cells infusion. Presence of uncontrolled infection, cardio-cerebrovascular disease,coagulopathy, or connective tissue disease. History of HIV infection Prior chimeric antigen receptor cellular immunotherapy targeting CD19 Pregnant or lactating patients
引自 ClinicalTrials.gov, NCT06365671, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06365671,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。